FDA grants Orphan Drug Designation to REYOBIQ from Plus Therapeutics (PSTV)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Plus Therapeutics reported that the U.S. FDA has granted Orphan Drug Designation to its radiotherapeutic candidate REYOBIQ (rhenium Re186 obisbemeda) for treating pediatric malignant gliomas, a group of rare, aggressive brain tumors with limited options and poor outcomes.
The designation, which also encompasses pediatric ependymoma, offers potential benefits such as seven years of market exclusivity upon approval, tax credits for clinical trial costs, and certain fee exemptions. It builds on prior regulatory and clinical progress for REYOBIQ in leptomeningeal metastases and pediatric brain cancers, where the drug is being studied in multiple ongoing ReSPECT trials.
Positive
- None.
Negative
- None.
Insights
FDA orphan designation is a meaningful regulatory milestone but still early-stage.
The FDA’s Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas signals official recognition of a high unmet medical need and the potential of this CNS-targeted radiotherapeutic. The scope is broader than requested, extending to pediatric ependymoma.
Economically, orphan status can improve the program’s attractiveness by offering 7 years of U.S. market exclusivity upon approval, tax credits for eligible trials, and regulatory fee reductions. These incentives may support continued development across indications like leptomeningeal metastases and recurrent glioblastoma.
However, this is not an approval and does not confirm safety or efficacy. Future value impact depends on outcomes from the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC studies and on whether subsequent FDA interactions, including potential pivotal trial designs, progress as the company expects.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Orphan exclusivity period: 7 years
Pediatric HGG incidence: 3.3 cases per 100,000 persons
Five-year survival for HGG: 22%
+5 more
8 metrics
Orphan exclusivity period
7 years
Market exclusivity in U.S. upon approval under Orphan Drug Designation
Pediatric HGG incidence
3.3 cases per 100,000 persons
Rarity of pediatric high grade gliomas including ependymoma
Five-year survival for HGG
22%
Five-year survival rates as low as 22% for pediatric high grade gliomas
LM occurrence in cancer
5%
Leptomeningeal metastases occurs in approximately 5% of people with cancer
LM survival at 1 and 2 years
7% at 1 year; 3% at 2 years
Survival rates for leptomeningeal metastases patients
CPRIT grant for ReSPECT-LM
$17 grant over three years
Funding from Cancer Prevention & Research Institute of Texas
DoD grant for ReSPECT-PBC
$3 million
U.S. Department of Defense Peer Reviewed Cancer Research Program
Breast cancer LM rate
3–5%
Portion of breast cancer patients who develop leptomeningeal metastases
Key Terms
Orphan Drug Designation, leptomeningeal metastases, Investigational New Drug (IND), radiotherapeutics, +2 more
6 terms
Orphan Drug Designation regulatory
"the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to REYOBIQ"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
leptomeningeal metastases medical
"LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid"
Leptomeningeal metastases occur when cancer cells spread to the thin layers of tissue covering the brain and spinal cord, similar to how weeds can invade the surface layer of soil. This condition often indicates advanced disease and can lead to serious neurological problems. For investors, the presence of such metastases may signal challenges in treatment options and can impact the outlook for related healthcare companies or research developments.
Investigational New Drug (IND) regulatory
"the Company has received FDA clearance of its Investigational New Drug (IND) application to evaluate REYOBIQ"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
radiotherapeutics medical
"a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies"
Radiotherapeutics are medical treatments that use tiny amounts of radioactive material to directly damage and kill diseased cells, most often cancer, by delivering radiation precisely to a tumor rather than the whole body. Investors care because these products combine drug development, specialized manufacturing and strict regulation—so clinical trial results, approval decisions, supply reliability and reimbursement determine commercial potential much like a new, precision tool transforming how a common problem is fixed.
leptomeninges medical
"spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord"
laboratory-developed tests technical
"develops and commercializes proprietary laboratory-developed tests, such as CNSide®"
FAQ
What did Plus Therapeutics (PSTV) announce about REYOBIQ in this 8-K?
Plus Therapeutics announced that the FDA granted Orphan Drug Designation to REYOBIQ for treating pediatric malignant gliomas. This recognizes the therapy’s potential in a rare, aggressive pediatric brain cancer setting with limited existing treatment options and poor patient outcomes.
What benefits does FDA Orphan Drug Designation provide to Plus Therapeutics (PSTV)?
Orphan Drug Designation can provide seven years of U.S. market exclusivity upon approval, tax credits for qualified clinical trial expenses, and exemptions from certain FDA regulatory fees. These incentives may help support REYOBIQ’s clinical development in rare CNS cancer indications.
How broad is the FDA orphan indication granted for REYOBIQ by Plus Therapeutics (PSTV)?
The FDA granted orphan designation for malignant glioma more broadly than Plus Therapeutics originally requested, encompassing pediatric ependymoma. This broader scope potentially expands the range of pediatric CNS tumors where REYOBIQ might be clinically developed and ultimately used if approved.
What clinical programs support REYOBIQ’s development at Plus Therapeutics (PSTV)?
REYOBIQ is being studied in the ReSPECT-GBM trial for recurrent glioblastoma, ReSPECT-LM for leptomeningeal metastases, and ReSPECT-PBC for pediatric brain cancer. These Phase 1 and Phase 2 studies provide clinical and regulatory groundwork across multiple central nervous system tumor indications.
How severe are pediatric malignant gliomas targeted by Plus Therapeutics’ REYOBIQ?
Pediatric malignant gliomas are high-grade, fast-growing brain tumors with poor prognosis and limited treatments. Standard surgery and radiation often fail to prevent recurrence, and five-year survival rates can be as low as 22%, highlighting the significant unmet medical need in this population.
What external funding supports Plus Therapeutics’ REYOBIQ clinical trials?
The ReSPECT-GBM trial is supported by a National Cancer Institute award, ReSPECT-LM is funded by a three-year $17 grant from the Cancer Prevention & Research Institute of Texas, and the ReSPECT-PBC pediatric trial is backed by a $3 million U.S. Department of Defense grant.